drugset / Trial / NCT03847506

Evaluate Efficacy and Safety of Ezetimibe/Rosuvastatin and Candesartan Cilexetil/Amlodipine Besylate Combination Tablets

NCT03847506

Phase 4 Completed 127 enrolled HK inno.N Corporation
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the efficacy and the safety of concomitant use of Ezetimibe/Rosuvastatin combination tablets and Candesartan cilexetil/Amlodipine besylate combination tablets compared to each combination tablet alone in patients with essential hypertension (HTN) and hyperlipidemia.

Timeline

Start
2018-07-05
Primary completion
2020-12-02
Completion
2020-12-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Amlodipine Other / unclassified 5 mg
Comparator Candesartan cilexetil Unknown 8 mg
Subject Ezetimibe Unknown 10 mg
Subject Rosuvastatin Small molecule 10 mg

Indications